PLEK2 is identified as an prognosis factor for prostate cancer, lung adenocarcinoma and head and neck squamous cell carcinoma in independent bioinformatics analysis with gene signature-based risk assessment models (Yin et al., 2016; Jiang et al., 2020; Wang et al., 2020, 2021b; Zhang et al., 2020). Here, PLEK2 is linked to Familial prostate cancer.